Skip to content

clinical study to evaluate the safety and efficacy of Dimad e baras in baras (Vitiligo)

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of Dimad-E- Baras (Topical) Compared With Methoxasalen 1 Percent(Topical) In The Management Of Baras (Vitiligo) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/081572
Enrollment
60
Registered
2025-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Dimad-e-Baras: Dimad-e-Baras containing Bekh-e-Anjeer Dashti, Babchi ,Tukhm-e-Panwar, Narkachor ,Abe lemu will be used topically on vitiliginous lesions followed by sun exposure daily

Sponsors

National Research Institute of Unani Medicine for Skin Disorders
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants having Non segmental vitiligo with Chronicity of 6 months to 3 years 2.Vitiligo involving more than 2 percent Body Surface Area (BSA) 3.Participants with less than 5 new lesions in the last month 4.Participants with less than 15 lesions in the last 3 months 5.Participants who have not taken systemic and tropical treatment in the last 4 week

Exclusion criteria

Exclusion criteria: 1.Participants aged less than 18 years or more than 60 years 2.Participants with Segmental vitiligo/acrofacial vitiligo/mucosal vitiligo and vitiligo universalis 3.Participants with history of any other skin disorders and inflammatory condition of the skin 4.Pregnant or Lactating Women 5.Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction 6.Known cases of Diabetes Mellitus 7.Known cases of Immunocompromised states

Design outcomes

Primary

MeasureTime frame
Change In Vitiligo Area Scoring Index (VASI)Timepoint: 0,2,4 and 8 weeks

Secondary

MeasureTime frame
1.Improvement in Patient s Global Assessment (PGA) on VAS for Vitiligo 2.Improvement in Investigator s Global Assessment (IGA) for Vitiligo 3.Improvement in QoL on VIS-22 (Assessment of Patient s Quality of Life) Timepoint: 0 and 8 weeks

Countries

India

Contacts

Public ContactDr Hina Kausar

National Research Institute of Unani Medicine for Skin Disorders

drashfaque6@gmail.com8103161174

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026